Impact of first-line antifungal agents on the outcomes and costs of candidemia

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 7, 2012, Pages 3950-3956

  Ha, Young Eun ^a   Peck, Kyong Ran ^a   Joo, Eun Jeong ^a   Kim, Shin Woo ^b   Jung, Sook In ^c   Chang, Hyun Ha ^b   Park, Kyong Hwa ^c   Han, Sang Hoon ^d  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Kyungpook National University Hospital   (South Korea)

^c Chonnam National University Medical School   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CANDIDEMIA; COST BENEFIT ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG TREATMENT FAILURE; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; LENGTH OF STAY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SOUTH KOREA; TERTIARY HEALTH CARE; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDEMIA; DEOXYCHOLIC ACID; DRUG COMBINATIONS; FEMALE; HUMANS; ITRACONAZOLE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84862576890     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06258-11     Document Type: Article

References (22)

1. Arnold HM, et al. 2010. Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy 30:361-368.
2. Bassetti M, et al. 2007. Incidence, risk factors, and predictors of outcome of candidemia: survey in 2 Italian university hospitals. Diagn. Microbiol. Infect. Dis. 58:325-331.
3. Bouza E, Munoz P. 2008. Epidemiology of candidemia in intensive care units. Int. J. Antimicrob. Agents 32(Suppl 2):S87-S91.
4. Craver CW, Tarallo M, Roberts CS, Blanchette CM, Ernst FR. 2010. Cost and resource utilization associated with fluconazole as first-line therapy for invasive candidiasis: a retrospective database analysis. Clin. Ther. 32:2467-2477.
5. Gagne JJ, Goldfarb NI. 2007. Candidemia in the in-patient setting: treatment options and economics. Expert Opin. Pharmacother. 8:1643-1650.
6. Girao E, et al. 2008. Seven-year trend analysis of nosocomial candidemia and antifungal (fluconazole and caspofungin) use in Intensive Care Units at a Brazilian University Hospital. Med. Mycol. 46:581-588.
7. Golan Y, Wolf MP, Pauker SG, Wong JB, Hadley S. 2005. Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis. Ann. Intern. Med. 143:857-869.
8. Jung SI, et al. 2010. Multicenter surveillance of species distribution and antifungal susceptibilities of Candida bloodstream isolates in South Korea. Med. Mycol. 48:669-674.
9. Kett DH, Azoulay E, Echeverria PM, Vincent JL. 2011. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit. Care Med. 39:665-670.
10. Kim SI, Kang MW. 2010. Current usage and prospect of new antifungal agents in Korea. Infect. Chemother. AID 42:209-215.
11. Kludze-Forson M, Eschenauer GA, Kubin CJ, Della-Latta P, Lam SW. 2010. The impact of delaying the initiation of appropriate antifungal treatment for Candida bloodstream infection. Med. Mycol. 48:436-439.
12. Pappas PG, et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
13. Picazo JJ, Gonzalez-Romo F, Candel FJ. 2008. Candidemia in the critically ill patient. Int. J. Antimicrob. Agents 32(Suppl 2):S83-S85.
14. Reboli AC, et al. 2011. Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients. Pharmacoeconomics 29:705-717.
15. Rentz AM, Halpern MT, Bowden R. 1998. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin. Infect. Dis. 27:781-788.
16. Shorr AF, et al. 2009. Burden of early-onset candidemia: analysis of culture-positive bloodstream infections from a large U.S. database. Crit. Care Med. 37:2519-2526.
17. Taur Y, Cohen N, Dubnow S, Paskovaty A, Seo SK. 2010. Effect of antifungal therapy timing on mortality in cancer patients with candidemia. Antimicrob. Agents Chemother. 54:184-190.
18. Vazquez JA. 2010. Invasive fungal infections in the intensive care unit. Semin. Respir. Crit. Care Med. 31:79-86.
19. Wingard JR, et al. 2005. Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysis. Clin. Ther. 27:960-969.
20. Zaoutis TE, et al. 2005. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin. Infect. Dis. 41:1232-1239.
21. Zilberberg MD, et al. 2010. Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study. BMC Infect. Dis. 10:150.
22. Zilberberg MD, Kothari S, Shorr AF. 2009. Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation. Crit. Care 13:R94.